Savara jumping to the NYSE in reverse merger with zombie biotech Mast
After raising $20 million and laying out plans for a Phase III pivotal trial of a reformulated antibiotic, Savara is getting the new year underway with a public listing, courtesy of a reverse merger with the zombie biotech Mast Therapeutics.
Mast had already fallen into penny stock status last September when the company $MSTX was forced to concede that its Phase III study of a new drug for sickle cell disease had failed, leaving the San Diego-based biotech with few remaining options.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.